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ABSTRACT  25 
We hypothesized that acute dietary nitrate (NO3
-) provided as concentrated beetroot juice 26 
supplement would improve endurance running performance of well-trained runners in 27 
normobaric hypoxia. Ten male runners (mean (SD): sea level V̇O2max 66 (7) mL
.kg-1.min-1, 10 28 
km personal best 36 (2) min) completed incremental exercise to exhaustion at 4000 m and a 10 29 
km treadmill time trial at 2500 m simulated altitude on separate days, after supplementation 30 
with ~7 mmol NO3
- and a placebo, 2.5 h before exercise. Oxygen cost, arterial oxygen 31 
saturation, heart rate and ratings of perceived exertion (RPE) were determined during the 32 
incremental exercise test. Differences between treatments were determined using means [95% 33 
confidence intervals], paired sample t-tests and a probability of individual response analysis. 34 
NO3
- supplementation increased plasma [nitrite] (NO3
-, 473 (226) nM vs. placebo, 61 (37) nM, 35 
P < 0.001) but did not alter time to exhaustion during the incremental test (NO3
-, 402 (80) s vs. 36 
placebo 393 (62) s, P = 0.5) or time to complete the 10 km time trial (NO3
-, 2862 (233) s vs. 37 
placebo, 2874 (265) s, P = 0.6). Further, no practically meaningful beneficial effect on time 38 
trial performance was observed as the 11 [-60 to 38] s improvement was less than the a priori 39 
determined minimum important difference (51 s), and only three runners experienced a ‘likely, 40 
probable’ performance improvement. NO3- also did not alter oxygen cost, arterial oxygen 41 
saturation, heart rate or RPE. Acute dietary NO3
- supplementation did not consistently enhance 42 
running performance of well-trained athletes in normobaric hypoxia.  43 
 44 
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INTRODUCTION 47 
Exposure to altitude has a profound negative effect on exercise performance because reduced 48 
partial pressure of ambient oxygen causes arterial oxygen desaturation, tissue hypoxia and 49 
disturbed muscle metabolism (Modin et al. 2001). Increasing dietary nitrate via beetroot 50 
supplementation (NO3
-) is an increasingly popular strategy to improve exercise capacity at sea 51 
level (Hoon et al. 2013). As conjectured by previous publication, NO3
- supplementation may 52 
be particularly effective at altitude due to its ‘oxygen sparing effect’ whereby whole body 53 
oxygen utilisation is reduced during submaximal exercise (Larsen et al. 2007; Bailey et al. 54 
2009; Vanhatalo et al. 2010; Lansley et al. 2011). The mechanism by which NO3
- 55 
supplementation has this effect is not completely understood but is likely related to increased 56 
plasma nitrite (NO2
-) concentration and nitric oxide (NO) production.  57 
 58 
As a physiological signalling molecule, NO plays a key role in the regulation of blood flow, 59 
mitochondrial respiration and biogenesis, muscle contractility, and glucose and calcium 60 
homeostasis (Stamler and Meissner 2001). New evidence also suggests a high NO 61 
bioavailability is characteristic of successful adaptation to altitude (Levett 2011). This notion 62 
is supported by increased concentrations of expired NO and plasma NO2
- observed in Tibetan 63 
highlanders (Beall et al. 2001; Erzurum et al. 2007). Theoretically, compared with sea level, 64 
dietary NO3
- supplementation at altitude may be more beneficial as the reduction process of 65 
NO3
- to NO is enhanced under acidic (Modin et al. 2001) and hypoxic conditions (Castello et 66 
al. 2006), whereas the endogenous L-arginine NO synthase (oxygen dependent) pathway is 67 
supressed.  68 
 69 
Studies investigating the effects of dietary NO3
- supplementation on exercise at high altitude or 70 
normobaric hypoxia are limited, but in general support beneficial effects (Vanhatalo et al. 2011; 71 
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Masschelein et al. 2012; Muggeridge et al. 2014). Specifically, Masschelein and colleagues 72 
(2012) showed partial restoration of oxygen delivery and utilisation in hypoxia, reporting 73 
increased arterial and muscle oxygenation during exercise after NO3
-
 ingestion compared with 74 
a placebo. Additionally, this and another study (Vanhatalo et al. 2011) demonstrated that dietary 75 
NO3
- supplementation improves exercise capacity in hypoxia, as time-to-exhaustion on an 76 
incremental cycling test (Masschelein et al. 2012) and leg extension exercise (Vanhatalo et al. 77 
2011) were longer after NO3
- was ingested. Unfortunately, these studies only demonstrated 78 
statistically significant differences between NO3
- consumption compared with a placebo, of 79 
which the practical performance benefit remained unclear. To address this issue, Muggeridge 80 
and colleagues (2014) investigated the benefit of NO3
- ingestion on trained cyclists during a 16 81 
km time trial at 2500m, and found both a statistically significant and practically meaningful 82 
(2.2%) improvement in performance time. Although these results draw attention to the potential 83 
endurance performance benefits of NO3
- supplementation, there is a requirement for further 84 
studies that investigate acute supplementation protocols, in well-trained athletes, using 85 
practically relevant outcome measures, to determine if NO3
- supplementation can enhance 86 
athletic performance such as endurance running capacity in hypoxia (Hoon et al. 2013; Jones 87 
2013). In addition, anecdotal reports obtained from national level altitude training camps 88 
indicate the possibility of responders and non-responders to ergogenic supplements including 89 
NO3
-, but scientific evidence is lacking to support this observation.  90 
 91 
With an increasing number of athletic camps and competitive running events now held at 92 
altitude each year, well trained runners are increasingly utilising NO3
- supplements despite 93 
minimal evidence of their ergogenic effect. The current investigation therefore aimed to assess 94 
the influence of acute NO3
- ingestion, via beetroot juice, upon endurance running performance 95 
and exercise tolerance at moderate altitude, in a well-trained population. It was hypothesised 96 
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that compared to a placebo, acute ingestion of a commercially available high-nitrate beetroot 97 
juice shot (~7 mmol NO3
-) would statistically (beyond chance) and practically (greater than the 98 
minimum important difference in the majority of participants) enhance exercise performance 99 
in normobaric hypoxia.  100 
 101 
METHODS 102 
Participants 103 
Ten well-trained competitive male runners (mean (SD): age 37 (13) years, height 1.78 (0.06) 104 
m, body mass 72 (7) kg, sea level V̇O2max 66 (7) mL.kg-1.min-1, 10 km personal best time 36 105 
(2) min) were recruited using opportunistic sampling methods from local running clubs between 106 
January and March 2013. Inclusion criteria detailed: a sub-40 min 10 km run time in the 107 
previous 12 months, non-smoking, and no exposure to altitude greater than 1500 m in the 108 
previous six months. All participants provided written informed consent. Ethical approval was 109 
granted by the Ethics Committee of the School of Sport, Health and Exercise Sciences at 110 
Bangor University (reference ID; MSc03-12/13), and the study was registered on 111 
www.clinicaltrials.gov (reference ID: NCT01795534). 112 
 113 
Design 114 
Participants visited the laboratory on six occasions (Figure 1). The first and second visits were 115 
used to familiarise participants with the experimental exercise tests, which involved completion 116 
of a 10 km treadmill time trial at a simulated 2500 m (FiO2, 15.4%) and an incremental exercise 117 
test to exhaustion at sea level. This incremental exercise test was also used to determine 118 
maximal oxygen uptake ( O2max) at sea level. The study then used a double-blind repeated 119 
measures crossover design where participants received either acute beetroot juice ingestion 120 
(NO3
-) or placebo ingestion (PLAC) in a random order. The randomisation was completed by 121 
V
.
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JHM using www.randomization.com. A minimum four-day wash out was used between 122 
supplementations to ensure circulating NO3
- and NO2
- concentrations returned to basal levels 123 
(Wylie et al. 2013). During each supplementation period participants visited the laboratories on 124 
two occasions. The first visit consisted of an incremental exercise test to exhaustion on a 125 
treadmill at a simulated 4000 m (FiO2, 12.8%). This relatively high altitude was chosen to 126 
maximise hypoxemia and thus potentiate any physiological effects of NO3
- supplementation 127 
(enhanced production of NO via exogenous NO3
-
 reduction occurs in hypoxic conditions 128 
(Castello et al. 2006)). The second visit consisted of a 10 km treadmill time trial at a simulated 129 
2500 m (FiO2, 15.4%), which directly tested moderate altitude endurance performance as 130 
required for events such as the Trans Alps Run, Tour de France, Pikes Peak Marathon and 131 
training camps (Wilber 2004).  132 
 133 
*PLEASE INSERT FIGURE 1 NEAR HERE*  134 
 135 
Supplementation 136 
Supplementation consisted of either a single 70 mL concentrated shot of beetroot juice (~7 137 
mmol NO3
-, Beet It SportTM, James White Drinks Ltd, Ipswich, UK) or a NO3
- depleted placebo 138 
shot that was identical in appearance, taste and texture (~0.003 mmol NO3
-, James White Drinks 139 
Ltd, Ipswich, UK). Placebo shots were created by passing the NO3
- active beetroot juice through 140 
a Purolite A520E NO3
- selective ion exchange resin before pasteurisation (Lansley et al. 2011). 141 
Supplements were ingested under experimenter supervision 2 h before visits three to six, which 142 
was 2.5 h before each exercise test. Shots were packaged in identical coded containers by James 143 
White Drinks and were distributed by JHM to participants, ensuring blinding of participants 144 
and observers (JTA, TLJ, SJO). To ensure that the placebo had been theoretically effective, a 145 
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manipulation check was conducted after each visit, asking participants to guess what 146 
intervention (NO3
- or placebo) they had received. 147 
 148 
Procedures 149 
One week before testing, participants were fully briefed with regards to the study aims and 150 
design. A list of high NO3
- foodstuffs to avoid throughout the study was presented to each 151 
participant in an attempt to isolate supplemented NO3
- as a cause of any potential effect. 152 
Participants were asked to not increase or decrease training load throughout the study. 153 
Furthermore, twenty four hours before the first familiarisation session, each participant was 154 
asked to produce a diet and activity diary and to repeat these recorded behaviours in the twenty 155 
four hours prior to all trials. Participants were also allocated drinking water equal to 35 mL.kg-156 
1 of body mass to be consumed in the 24 hours prior to each visit. Participants were asked to 157 
abstain from the use of any chewing gum or antibacterial mouthwashes as this has previously 158 
shown to lessen the reduction of NO3
- to NO2
- by commensal bacteria within the oral cavity 159 
(Govoni et al. 2008). These actions were then repeated for subsequent visits.  160 
 161 
Each participant completed all exercise tests at the same time of day. At the start of each visit 162 
body mass was measured and urine and capillary blood samples were obtained to ensure runners 163 
were euhydrated (urine specific gravity less than 1.020, refractometer Atago, Japan (Oppliger 164 
et al. 2005)) and had normal hemoglobin (greater than 13.5 g·dL-1, Hemocue Ltd, Derbyshire, 165 
UK). After, a resting venous blood sample was obtained by venepuncture into a lithium-heparin 166 
tube (Monovette Lithium Heparin, Sarstedt, Leicester, UK). This blood sample was placed in 167 
a centrifuge and spun at 4000 rpm at 4 °C for 10 min within 3 min of collection. Immediately 168 
after the centrifugation, plasma was aspirated into eppendorfs and frozen at -80 °C for a 169 
standardised time period prior to subsequent analysis of NO availability (NO2
- and NO3
- 170 
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concentration) as per Wylie et al. (2013). All subsequent data collection was conducted in a 171 
temperature and humidity controlled normobaric hypoxic environmental chamber (Hypoxico 172 
Inc., The Altitude Centre, London, UK, 20.0 (0.1) °C, 40 (3) %). 173 
 174 
Incremental exercise test 175 
The chamber was set and maintained at a simulated altitude of 4000 m (ambient oxygen 12.9 176 
(0.1) %). Maximal oxygen uptake was assessed using a continuous incremental exercise test on 177 
a motorised treadmill (h/p/cosmos, Nussdorf, Germany) until volitional exhaustion. The test 178 
started at 10 km.h-1 with a 0% gradient. Increments were subsequently achieved by increasing 179 
the treadmill speed by 1 km.h-1 every minute until 16 km.h-1. Thereafter the gradient was 180 
increased by 1% every minute until volitional exhaustion. Following a period of active 181 
recovery, where the participant completed light exercise until their heart rate reduced to less 182 
than 100 bpm, V̇O2max was verified by runners returning to the treadmill to complete exercise 183 
at an intensity greater than at exhaustion (i.e. 1% greater gradient). Oxygen consumption was 184 
recorded continuously throughout exercise by a metabolic cart (Metalyser, Cortex, Leipzig, 185 
Germany) with V̇O2max determined as the highest 30 s average at any given time point. 186 
Additionally heart rate by remote transmitter (FT3, Polar, Kempele, Finland), blood oxygen 187 
saturation by fingertip pulse oximeter (7500, Nonin Medical Inc., Minnesota, USA) and overall 188 
rating of perceived exertion (RPE) by Borg CR100 scale (Borg and Borg 2001), were recorded 189 
during the final 15 s of each incremental stage. At exhaustion, blood lactate was also measured 190 
via ear lobe capillary sampling and a portable analyser (Lactate Pro, Ark Ray Inc, Kyoto, 191 
Japan).  192 
  193 
 194 
 195 
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Time Trial 196 
The chamber was set and maintained at a simulated altitude of 2500 m (ambient oxygen 15.4 197 
(0.1) %). After runners had completed a standardised warm up of 3 min at 10 km.h-1 they 198 
completed a 10 km time trial on a treadmill. Treadmill gradient was set to 1% to better replicate 199 
the physiological demands of outside running (Jones and Doust 1996). Runners were instructed 200 
to complete the distance as quickly as possible. During the time trial runners were blinded to 201 
the elapsed time and speed of the treadmill. Verbal prompts at kilometre intervals were provided 202 
to replicate distance markers during running race competitions. Runners self-selected their 203 
running speed throughout the time trial. Differentiated RPE (legs, chest and overall) was 204 
recorded at the completion of each time trial kilometre to assess trends in pacing. The reliability 205 
of this 10 km time trial protocol at 2500 m simulated altitude was assessed in six similarly 206 
trained runners to be 3.9 (1.0) % (within subjects coefficient of variation), across three time 207 
trials each separated by seven days. The within subjects coefficient of variation of the second 208 
and third time trial alone was assessed to be 2.1 (1.4) %.  209 
 210 
Data Analysis 211 
The primary outcome measure was time to complete the 10 km treadmill time trial. All data 212 
extraction was completed whilst experimenters were blinded; only statistical analyses were 213 
completed un-blinded. Data are presented as means (SD) or [95% confidence interval]. 214 
Inferential statistical analysis was conducted using the software package SPSS (version 20, 215 
IBM, Portsmouth, UK). Statistical significance was set at P ≤ 0.05. To evaluate the statistical 216 
significance of NO3
- supplementation, paired samples t-tests were used to assess differences 217 
between NO3
- and placebo trials. Magnitude of difference between treatments was calculated 218 
as NO3
- minus placebo trial and for the primary outcome measure compared to a minimal 219 
practical important difference determined as 51 s (Cohen’s smallest important effect: 0.2 × 220 
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between subject SD, confirmed by discussion with expert coaches, and equivalent to 1.8%). A 221 
probability analysis was also undertaken on the primary outcome measure, estimating the 222 
likelihood of a true positive response to NO3
- supplementation (Hopkins 2000). Specifically, 223 
using calculations on precision of change provided by Hopkins (2000), for each runner the 224 
difference between NO3
- and placebo trials was assigned one of the following verbal descriptors 225 
to describe if NO3
- supplementation had a positive effect on their individual time trial 226 
performance: ‘almost certainly not’; ‘very unlikely’;  ‘unlikely, probably not’; ‘possibly may’; 227 
‘likely probable’; ‘very likely’; ‘almost certainly’. Data from the incremental test (i.e. 228 
physiological parameters such as oxygen uptake) were presented and analysed at maximal 229 
exercise capacity (100% altitude specific V̇O2max), and at a submaximal workload (45% 230 
altitude specific V̇O2max). In order to investigate NO2- response, baseline plasma NO2- 231 
concentrations and also the difference between NO3
- and placebo trials’ plasma NO2- 232 
concentrations were correlated (Pearson’s r) against the difference between NO3- and placebo 233 
trials for all outcome measures. Finally, post hoc independent t-tests were completed to explore 234 
if baseline characteristics (age, body mass, V̇O2max, haemoglobin), plasma NO2- responses 235 
(plasma NO2
- concentrations on the placebo trial and difference between NO3- and placebo 236 
trials’ plasma NO2- concentrations) or hypoxia responses (average arterial oxygen saturation 237 
on the placebo trial) may explain why some individuals improved time trial performance after 238 
NO3
- supplementation.         239 
 240 
For the primary outcome, sample size estimation was completed using both statistical 241 
significance and magnitude based inference methods (Hopkins 2006). Data on expected 242 
reliability of the 10 km time trial between two trials after a familiarisation trial was obtained 243 
from a pilot study on six well trained athletes: the Pearson’s correlation coefficient was 0.98, 244 
the between subject SD was 255 s, and the typical error was 33 s. The minimum practical 245 
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important difference was therefore set at 51 s. Using the magnitude based inference method 246 
and maximum chances of Type I and Type II clinical errors of 0.5 and 25% respectively, six 247 
participants were estimated as required to detect a difference in means in a post-only 248 
crossover trial. Using the statistical significance method and maximum rates of Type I and 249 
Type II statistical errors of 5 and 20%, respectively, nine participants were required.    250 
 251 
RESULTS 252 
The NO3
- and placebo shots effectively altered the independent variable: 2.5 h after NO3
- 253 
consumption plasma [NO3
-] and [NO2
-] were significantly greater than after placebo ([NO3
-] in 254 
the NO3
- trial, 201.6 (25.9) μM vs. placebo trial, 28.9 (6.4) μM, P < 0.001; [NO2-] in the NO3- 255 
trial, 473 (226) nM vs. placebo trial, 61 (37) nM, P < 0.001). The runners were considered to 256 
be sufficiently well blinded as to which supplement they received on each visit, as the 257 
manipulation check indicated that only two participants of ten guessed correctly, two guessed 258 
incorrectly, and six were unable to distinguish between the supplements at all. 259 
 260 
Incremental exercise test 261 
Acute NO3
- supplementation did not alter any measured physiological variable or RPE during 262 
maximal or submaximal exercise at 4000 m (Table 1). No statistical difference was present in 263 
any parameter obtained at 100% or 45% of V̇O2max. There was also no practical performance 264 
difference in time to exhaustion between trials (NO3
- – placebo: Δ 1.4%). No correlations were 265 
observed between baseline plasma [NO2
-] or the change in plasma [NO2
-] with any maximal 266 
exercise parameter.  267 
 268 
*PLEASE INSERT TABLE 1 NEAR HERE*  269 
 270 
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Time Trial 271 
Acute NO3
- supplementation did not improve 10 km running performance at simulated altitude 272 
(2500 m). No statistical difference was observed in time to complete the 10 km time trial (NO3
-273 
, 2862 (233) s vs. placebo, 2874 (265) s, P = 0.6). Additionally, compared to the a priori 274 
determined minimum practical important difference of -51 s (1.8%) there was also no practical 275 
difference in performance (NO3
- – placebo: Δ -11 [-60 to 38] s or Δ 0.4%: Figure 2). Trends in 276 
RPE during the time trial were visually explored but no difference was observed between NO3
- 277 
and placebo. 278 
 279 
*PLEASE INSERT FIGURE 2 NEAR HERE*  280 
 281 
Results obtained from the probability analysis suggested that three runners experienced a 282 
performance improvement with NO3
- supplementation labelled ‘likely, probable’; one runner 283 
experienced impaired performance labelled ‘likely, probable’; and the remaining six runners 284 
exhibited no strong probability of either improved or impaired performance. Further, no 285 
correlation was observed between baseline [NO2
-] or the change in plasma [NO2
-] with change 286 
in time to complete the 10 km time trial (r < 0.48, P > 0.1).  287 
 288 
Exploratory post hoc analyses suggested that runners who improved time trial performance 289 
responded to hypoxia with greater arterial desaturation, as indicated by lower arterial oxygen 290 
saturation during the placebo time trial (82 (2) vs. 84 (2), P = 0.04). There was however no 291 
difference in baseline characteristics (age, body mass, O2max, haemoglobin, P > 0.4) or plasma 292 
NO2
- responses (plasma NO2
- concentrations on the placebo trial and difference between NO3- 293 
and placebo trials’ plasma NO2- concentrations, P > 0.6) between those runners that did or did 294 
not improve time trial performance after NO3
- supplementation. 295 
V
.
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DISCUSSION 296 
The current study aimed to assess the influence of NO3
- supplementation upon endurance 297 
running performance at altitude in well-trained runners. The principal finding contradicted the 298 
hypothesis: acute NO3
- supplementation did not enhance endurance running performance in 299 
normobaric hypoxia. Specifically, no statistical or practical difference in 10 km time trial 300 
running performance was observed between NO3
- and placebo trials, whilst probability analysis 301 
of individual responses suggested only three of ten participants had a “likely, probably” 302 
increase in performance. In addition, no significant differences were seen in any measured 303 
physiological or perceptual parameters or time to exhaustion during an incremental treadmill 304 
test in normobaric hypoxia. These findings contrast those of other investigations conducted in 305 
hypoxia that have suggested positive effects of NO3
- supplementation on time to exhaustion 306 
(Vanhatalo et al. 2011; Masschelein et al. 2012) and time trial performance (Muggeridge et al. 307 
2014). 308 
 309 
It is unlikely that the acute nitrate dose of 7 mmol NO3
- administered in the present study was 310 
simply insufficient to cause an effect. In a previous dose response study completed in normoxia, 311 
time to exhaustion was improved after acute NO3
- supplementation equal to 8 mmol of dietary 312 
NO3
- (Wylie et al. 2013). The positive effects in hypoxia on exercise tolerance previously 313 
observed by Vanhatalo et al. (2011) and Massechelein et al. (2012) and on exercise performance 314 
by Muggeridge et al. (2014) were achieved with NO3
- doses that ranged from smaller (5 mmol) 315 
to larger (9 mmol acutely and 5 mmol once daily for six days) doses than used in the present 316 
investigation. Considering that suppression of the endogenous L-arginine NO synthase (oxygen 317 
dependent) pathway occurs in hypoxia (Castello et al. 2006), suggesting a greater reliance on 318 
reduction of NO3
- to NO (potentially reducing the required dose to have a physiological effect), 319 
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the non-significant finding following dietary supplementation of NO3
- in the present study 320 
remains surprising.  321 
 322 
Theoretically the negative finding of the current investigation may be explained by the well-323 
trained status of the participants recruited (Hoon et al. 2013). Sea level studies have shown that 324 
the beneficial effects of NO3- supplementation on exercise performance may be reduced in well-325 
trained athletes (Wilkerson et al. 2012), and thus well trained athletes may require longer 326 
periods of supplementation to elicit an ergogenic effect (Cermak et al., 2012a, 2012b). Well-327 
trained athletes have greater resting plasma NO3
- concentrations (Jungersten et al. 1997), 328 
greater presence of NO synthase (Green et al. 2004), and experience less severe localised 329 
hypoxia and acidosis in the muscle compared to untrained populations (Wilkerson et al. 2012). 330 
Such adaptations allow more NO to be derived from the endogenous NO synthase pathway, 331 
and place less reliance on NO3
- supplementation as a means to maintain adequate NO 332 
concentrations. However we hypothesized that such adaptations in well-trained athletes would 333 
be outweighed by the deleterious effects of hypoxia, allowing a benefit to be observed from 334 
acute nitrate supplementation even in well-trained athletes. Unfortunately the current findings 335 
do not support this hypothesis. As comparison of training status of participants between studies 336 
completed in hypoxia is difficult (Masschelein et al. 2012; Muggeridge et al. 2014; Vanhatalo 337 
et al. 2011), and because completing correlational analyses between baseline fitness or baseline 338 
NO bioavailability and response to supplementation is problematic in homogenous groups such 339 
as recruited herein, an important future direction for research in this area is to investigate the 340 
moderating effect of training status in response to NO3
- supplementation.   341 
 342 
It is also possible that the effects of NO3
- on exercise performance in hypoxia may in part be 343 
dependent upon exercise mode, duration and intensity. Some previous investigations have 344 
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utilised exercise protocols that are arguably less ecologically valid, over-estimating ergogenic 345 
effects of any intervention (Masschelein et al. 2012; Vanhatalo et al. 2011). In fact even within 346 
sea level studies that have specifically assessed performance through practically relevant time 347 
trial testing, the results of NO3
- supplementation remain mixed (Hoon et al. 2013). Perhaps of 348 
greatest relevance is the study by Muggeridge and colleagues (2014) that utilised a cycling time 349 
trial in hypoxia, which revealed positive effects of NO3
- supplementation. Of interest, the 350 
utilised time trial was noticeably shorter in duration than the test used in the current study (28 351 
vs. 48 min). Possibly the effect size of NO3
- supplementation is reduced in longer duration 352 
activities (Wilkerson et al. 2012). The mechanism remains unknown, but during shorter 353 
duration exercise more type II muscle fibres are recruited, and recent findings suggest the 354 
effects of NO3
- are perhaps preferential to type II fibres (Hernandez et al. 2012; Ferguson et al. 355 
2013). 356 
 357 
Whilst these mechanistic explanations are speculative, detailed analysis within the present 358 
study of individual responses clearly show that the performance benefit of NO3
- 359 
supplementation is very variable. A probability analysis addressing the true likelihood of 360 
individual responses to NO3
- supplementation suggested that three participants experienced a 361 
‘likely/probable’ improvement in performance when supplemented with NO3-, one participant 362 
experienced a ‘likely/probable’ decrease in performance, whilst the remaining participants had 363 
no strong probability of either enhanced or impaired performance. The reason for the improved 364 
performance in some but not all individuals is of particular interest. A placebo effect can be 365 
excluded as all three participants with improved performance could not differentiate which 366 
supplement they were taking before each time trial. Exploratory post hoc analysis suggested 367 
that NO3
- supplementation improved time trial performance in those runners that had the 368 
greatest arterial desaturation in hypoxia. As this exploratory post hoc analysis was completed 369 
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in small numbers, future studies are required to confirm whether individual susceptibility to 370 
hypoxia moderates performance benefits of NO3
- supplementation. Future studies are also 371 
required to provide sufficient data for meta-analyses, before NO3
- can be accepted as an 372 
ergogenic aid in hypoxia.   373 
 374 
Criticisms of the current work include the use of well-trained athletes. Difficulties surrounding 375 
physiological testing of trained populations include other training and competition 376 
commitments. In order to control for such variables, athletes were encouraged to maintain 377 
consistent training load during the study; however compliance was only confirmed by 378 
inspection of training diaries. Nevertheless the consistency in which these athletes were able to 379 
complete the 10 km time trial, as shown by the acceptable reliability results, suggests that any 380 
effect of other training or competition exercise was minimal on the time trial results of this 381 
study. The acute exposure to hypoxia may be considered another limitation, as the influence of 382 
nitrate supplementation on exercise during longer exposures to hypoxia is unknown. However, 383 
as many athletes do not have adequate time to acclimatize to altitude before training or 384 
competition, the moderate altitude used for the time trial (2500 m) is typical of that experienced 385 
by athletes.  386 
 387 
Conclusion  388 
This investigation was unable to provide evidence for either a statistically significant or 389 
practically beneficial effect of acute NO3
- supplementation on 10km running performance or 390 
exercise tolerance in a maximal incremental test (both completed in normobaric hypoxia). 391 
These results contradict previous studies, most likely due to the inter-individual response to 392 
acute dietary NO3
- supplementation that was observed in the present investigation. Further 393 
investigation of the mechanistic reasons for inter-individual responses to supplementation is 394 
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thus required before NO3
- supplementation can be accepted as an effective ergogenic aid in 395 
hypoxia.  396 
 397 
  398 
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TABLES 
Table 1. Time to exhaustion and other psychophysiological responses at submaximal and 
maximal exercise intensities during an incremental treadmill exercise test at simulated altitude 
(4000 m) after acute dietary nitrate and placebo supplementation 
 NO3- PLAC NO3- - PLAC P 
Time to exhaustion (s) 402 ± 80 393 ± 62 9 [-20 to 38] 0.5 
45% V̇O2max     
Speed/Gradient (km.h-1 / %) 12 (0) / 0 (0) 12 (0) / 0 (0) - - 
V̇O2 (mL.kg-1.min-1) 26 (2) 26 (2) 0 [-1 to 1]  0.7 
SpO2 (%) 78 (3) 77 (5) 1 [-5 to 3] 0.6 
Heart rate (bpm) 136 (13) 134 (12) 1 [-9 to 6] 0.7 
Rating of perceived 
exertion 
24 (14) 25 (14) -1 [-6 to 7]  0.8 
100% V̇O2max     
Speed/Gradient (km.h-1 / %) 16 (0) / 1 (1) 16 (0) / 1 (1) - - 
V̇O2 (mL.kg-1.min-1) 48 (4) 48 (5) 0 [-2 to 1] 0.8 
SpO2 (%) 74 (3) 74 (4) 1 [-2 to 3] 0.7 
Heart rate (bpm) 155 (12) 158 (26) -3 [-19 to 12] 0.7 
Rating of perceived 
exertion 
79 (27) 79 (30) 0 [-6 to 6] 1.0 
[Blood lactate] (mmol.L-1) 8.8 (2.0) 8.3 (3.0) 0.5 [-1.2 to 2.1] 0.6 
Data are mean (SD) or mean difference [95% confidence interval]; significance determined by paired samples t-
test (n = 10); NO3-, 70ml dietary nitrate (beetroot juice) supplementation; PLAC, placebo supplementation; 
V̇O2max, maximal oxygen uptake at 4000 m; SpO2, arterial oxygen saturation; whole-body rating of perceived 
exertion by Borg CR100 scale.  
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FIGURE CAPTIONS 
Figure 1: Schematic representation of research design 
n, number of participants; V̇O2max, maximal oxygen uptake incremental exercise test; TT, 10 
km time trial.  
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Figure 2: Difference in performance during a simulated altitude (2500 m) 10 km time trial after 
acute dietary nitrate and placebo supplementation. 
NO3
-, 70 ml dietary nitrate (beetroot juice) supplementation; PLAC, placebo supplementation; 
horizontal lines = mean response [95% confidence interval]; dots = individual runner 
responses. The negative values indicate runners that completed the time trial sooner when 
supplemented with dietary nitrate than placebo 
 
